RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > In Focus: Due Diligence

In Focus: Due Diligence

Posted 01 July 2009 | By

This month we venture into the business side of regulatory with an issue concentrating on due diligence. Due diligence is usually thought of as an investigation of facts about a company or product by a concerned party, often a potential buyer. In the regulatory context, we would normally expect to see due diligence conducted as part of the acquisition of a company or product line. Particularly in the drug world, the regulatory status of products can be a deciding factor in a sale or merger. However, due diligence could also be internal: confirmation by management or others that certain regulatory steps have been taken, or that products are properly licensed and procedures correctly dealt with.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.